Clinical Trial Update: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) [Phase 1]

View source ↗

Summary

Phase 1 dose-exploration trial of Birabresib (MK-8628) in selected hematologic malignancies (AML variants and DLBCL) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndrome Related AML

Drugs mentioned

• birabresib (birabresib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: AML Including AML de Novo and AML Secondary to MDS, DLBCL | Phase 1 | Status: TERMINATED | Results posted: 2019-07-23